Health House International Limited (ASX:HHI) has signed a five year exclusive distribution agreement with Zelira Therapeutics Ltd in the United Kingdom.
The Distribution Agreement will further expand Health House’s product portfolio for cannabis products within the United Kingdom, adding the Zelira CBD toothpaste brand manufactured by Springjene in the United States of America, which represents a unique product offering in Oral Healthcare.
Health House Chief Operating Officer – UK & Europe, Tony Samios, saidthe Distribution Agreement expands Health House’s current portfolio of Zelira’s products which includes the non-exclusive rights to distribute Zenivol and the HOPE range of products throughout Australasia (including Australia, New Zealand and Asia) and the UK.
The Zelira CBD toothpaste brand manufactured by Springjene in the US, represents a unique product offering in Oral Healthcare which adds to Health House’s existing range of cannabis products,” Mr Samios said.
“It is made up of patented formulation of zinc, black seed oil and CBD which are thought to fight conditions like gingivitis and reduce gum inflammation and to which the addition of CBD could make this even more effective. We are pleased to be able to bring this product into the UK market and distribute it to our range of clients.”
Zelira Therapeutics CEO, Oludare Odumosu, said his company took a very strategic position in the cannabinoid-based consumer product segment with the successful launch of its first SprinjeneCBD oral care toothpaste product in the US.
“Health House International has established distribution networks in emerging markets such as the UK, and will be a key channel as we continue to grow our global distribution footprint. Through distribution partners like Health House International, Zelira is able to reach larger market segments and accelerate the delivery of quality CBD oral care products globally,” he added.
